Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus

Next Previous
X
Search
Trial Profile

A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 8521 (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 09 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 24 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 27 May 2014 According to ClinicalTrials.gov record, planned number of patients changed from 48 to 84. An additional cohort of T2DM participants and a cohort of non-diabetic obese participants have been added. Also modified inclusions-exclusion criteria and treatments

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top